Table 1.
Characteristics of patients with rheumatoid arthritis (RA) and hallux valgus deformity (N = 53).
| Characteristic | Results |
|---|---|
| Age * (y) | 64.8 ± 11.5 (32 to 85) |
| Male:female (no.) | 0:53 |
| Disease duration * (y) | 22.0 ± 12.0 (4 to 54) |
| Follow-up period * (y) | 4.6 ± 1.9 (2 to 7) |
| Body mass index * (kg/m2) | 21.5 ± 3.3 (17.5 to 29.4) |
| Steinbrocker stage (I, II, III, IV) (%) | 4, 8, 24, 64 |
| Steinbrocker class (I, II, III, IV) (%) | 42, 47, 11, 0 |
| DAS28-CRP * | 2.8 ± 0.7 (1.18 to 3.99) |
| Biologics usage (%) | 41.5 |
| Biologics (no.) | TCZ: 11, ABT: 4, IFX: 2, ETN: 2, CTZ: 2, GLM: 1 |
| MTX usage (%) | 67.9 |
| MTX dose * (mg/week) | 6.6 ± 2.0 (4 to 10) |
| Prednisolone usage (%) | 9.4 |
| Prednisolone dose * (mg/day) | 2.6 ± 1.2 (2 to 5) |
| Tibio-calcaneal angle * | 3.3 ± 6.8 (−6 to 26) |
| Meary’s angle * | 2.8 ± 9.7 (−32 to 37) |
| Ankylosis of the mid-foot (%) | 22.6 (12/53) |
* The data are presented as means and standard deviation with the range in parentheses. TCZ, tocilizumab; ABT, abatacept; IFX, infliximab; ETN, etanercept; CTZ, certolizumab pegol; GLM, golimumab; MTX, methotrexate; DAS28-CRP, disease activity score.